Main Industry
Biotechnology
Main Product/Service
Macular Drug Treatment: Anti-VEGF (anti-vascular endothelial growth factor) monoclonal antibodies Avastin® (bevacizumab), Lucentis® (ranibizumab), and Beovu® (brolucizumab)
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83066267
Status
Active
Number of Employees
0
Total Paid-in
Capital
8,000,000 (NT$)
Location of Company
Taiwan
, Kaohsiung City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Established in 2020, the company primarily focuses on novel drugs as its goal, and can accept commissions to develop various biotechnology products on behalf of clients. Currently, it is mainly developing "protein preparations" for application in ocular diseases such as macular degeneration and diabetic retinopathy, contributing its efforts to the future development of medicine.
The content above was translated by Ai
